Login to your account
The (often referred to simply as the IFM-05 study) focused on using lenalidomide as a maintenance treatment.
Due to the risk of secondary cancers identified in the IFM-05 trial, long-term monitoring for new symptoms or blood changes is standard practice for those on this regimen.
Research published around May 2022 explored the impact of "early" vs. "late" discontinuation (stopping before or after 3 years), noting that early stopping is often forced by toxicity rather than choice. IFM_05-May 2022
To determine if continuous low-dose chemotherapy after a transplant could improve overall survival and keep the disease controlled for longer periods.
Patients are encouraged to discuss the balance between disease control and the toxic long-term effects of maintenance drugs with their oncology team. The (often referred to simply as the IFM-05
A significant number of patients (roughly 27%) had to stop the maintenance therapy early due to adverse side effects.
Lenalidomide was the primary drug used for maintenance in this study. Key Findings: "late" discontinuation (stopping before or after 3 years),
One critical finding was an increased risk of developing a second primary malignancy (SPM) while on long-term lenalidomide maintenance. Patient Considerations